A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 253 participants.

Also called NCT01729871

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 253 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01729871
  • EudraCT 2012-001484-79
Other papers using this trial's data
  • Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation European heart journal, 2015-07-21 DOI, PubMed 25975659, PMC4508487 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, France, Germany, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01729871. Randomized; no masking; primary purpose treatment. Start 2013-02 (registry gives no type); primary completion 2014-10 (actual). Results posted on 2015-11-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy
Acronym
VENTURE-AF
Intervention (Drug)
rivaroxaban
Intervention (Drug)
uninterrupted vitamin K antagonist (VKA)
Lead sponsor
Janssen Scientific Affairs, LLC (class: industry)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct01729871
Content hash
d9ebad36282b7cc6d6e98cc84a49f833772b1f122f30b1736aa42021a4ddab72